US 12,410,129 B2
Crystalline 5-methoxy-N,N-diallyltryptamine compounds
Andrew R. Chadeayne, Issaquah, WA (US)
Assigned to CAAMTECH, INC., Issaquah, WA (US)
Filed by CAAMTECH, INC., Issaquah, WA (US)
Filed on Jul. 11, 2023, as Appl. No. 18/350,103.
Application 18/350,103 is a continuation of application No. 17/995,516, granted, now 11,739,060, previously published as PCT/US2021/025891, filed on Apr. 6, 2021.
Claims priority of provisional application 63/132,547, filed on Dec. 31, 2020.
Claims priority of provisional application 63/006,371, filed on Apr. 7, 2020.
Prior Publication US 2023/0348383 A1, Nov. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4045 (2006.01); A61K 45/06 (2006.01); C07D 209/16 (2006.01)
CPC C07D 209/16 (2013.01) [A61K 31/4045 (2013.01); A61K 45/06 (2013.01); C07B 2200/13 (2013.01)] 19 Claims
 
1. A composition comprising crystalline 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT) and an excipient.